moneyheap
DXCM · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is DexCom, Inc. (DXCM) stock moving?
DexCom beat Q3 2026 estimates on revenue ($1.344B vs $1.327B) and adjusted EPS ($0.73 vs $0.67), raised its FY2026 sales guidance floor to $5.200B, and authorized a $1B buyback, roughly 3% of its ~$29.7B market cap. Several brokers raised targets afterward, ranging from JP Morgan's Neutral $85 to Barclays' Overweight $120, with UBS at Buy $107 and Canaccord at Buy $97. Health Canada's myLoop approval on Nov 9 adds a fresh product-related positive. The price response has faded, however: after the Oct 30 gap to $82.29 and the Nov 4 high of $88.48, with an intraday high of $90.25 on Nov 5, the stock reversed to $79.92 on Nov 10, close to its Oct 29 close of $79.93. Volume has also tapered from 8.6M on Oct 30 to 3.1M on Nov 10, so the post-earnings move is losing momentum. Near-term direction looks unresolved until the Nov 17 Jefferies update. The fundamentals and analyst support lean positive, but the give-back of the earnings gains and the weak recent volume temper the short-term view.
News behind the analysis
- Dexcom Announces Upcoming Conference PresentationManagement will give a company update at the Jefferies Global Healthcare Conference in London on November 17, 2026.
- Health Canada Approves Dexcom G7 Integration with myLoopHealth Canada approved use of the Dexcom G7 CGM with the myLoop automated insulin delivery system, powered by CamAPS FX.
- DexCom Reports Q3 2026 Financial Results and Raises Revenue GuidanceQ3 2026 results beat analyst expectations for revenue and adjusted EPS, and full-year 2026 revenue guidance was raised.
- DexCom Raises FY2026 Sales Guidance from $5.180B-$5.250B to $5.200B-$5.250B vs $5.229B EstThe low end of FY2026 sales guidance was lifted to $5.200B, against an estimate of $5.229B.
- DexCom Q3 Adj. EPS $0.73 Beats $0.67 Estimate, Sales $1.344B Beat $1.327B EstimateAdjusted EPS of $0.73 and sales of $1.344B both came in above consensus estimates for the quarter.
- DexCom Board Authorizes $1 Billion Share Repurchase ProgramThe board approved a new buyback of up to $1 billion of outstanding common stock.
- Barclays Maintains Overweight on DexCom, Raises Price Target to $120Barclays kept an Overweight rating and lifted its price target to $120 after the quarterly report.
- UBS Adjusts DexCom Price Target to $107 From $102, Maintains Buy RatingUBS raised its price target to $107 from $102 and kept its Buy rating.
- JP Morgan Maintains Neutral on DexCom, Raises Price Target to $85JP Morgan kept a Neutral rating and raised its price target to $85, close to the current share price.
- Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $97Canaccord Genuity kept its Buy rating and raised its price target to $97.
About DexCom, Inc.
DexCom, based in San Diego, makes continuous glucose monitors (CGMs). These are small sensors worn on the body that track blood sugar in real time and send the readings to a phone or insulin pump. It is one of the two main players in this market. Its products include the G7 system (now with a 15-day sensor), plus Stelo, an over-the-counter sensor sold to people with type 2 diabetes who don't use insulin and to wellness users.
How it makes money
Nearly all of DexCom's revenue comes from selling CGM sensors, transmitters and receivers. Sensors are disposable and have to be replaced every 10–15 days, so the business earns repeat revenue from the same users. It sells through US pharmacies and durable medical equipment distributors, and is paid mostly by insurers and Medicare. International sales make up roughly a quarter of revenue. The company expects 2026 revenue of about $5.2 billion, which would be roughly 11–13% growth. Third-quarter 2026 revenue was about $1.34 billion, up about 11% from a year earlier.
What usually moves DXCM
- CGM adoption and insurance coverage for type 2 diabetes patients not on insulin
- Competition and pricing pressure, especially from Abbott's FreeStyle Libre
- Product launches and how well they're received, such as the G7 15-day sensor and Stelo
- Quarterly revenue growth and gross margin compared with company guidance
- Worries that GLP-1 weight-loss drugs could reduce demand for diabetes devices